Last 12 months
Inside the activity.
0 purchase rows · 33 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 1 |
| Dec 2025 | 0 | 2 |
| Jan 2026 | 0 | 2 |
| Feb 2026 | 0 | 4 |
| Mar 2026 | 0 | 5 |
| Apr 2026 | 0 | 2 |
| May 2026 | 0 | 3 |
| Jun 2026 | 0 | 3 |
| Jul 2026 | 0 | 3 |
| Aug 2026 | 0 | 5 |
| Sep 2026 | 0 | 2 |
| Oct 2026 | 0 | 1 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 19, 2026 Filed Feb 20, 2026 21:25 UTC |
Parisi Samuel JosephVP, Finance (Interim PAO)
|
Exercise / conversionOrdinary Shares | 2,991 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001520262-26-000029 · form4.xml · nonDerivative · entry 3 Parisi Samuel Joseph · CIK 0002010945 · VP, Finance (Interim PAO) 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,036 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share. Read SEC document |
| February 19, 2026 Filed Feb 20, 2026 21:23 UTC |
Jackson Blair CurtisEVP, Chief Operating Officer
|
Exercise / conversionRestricted Stock Unit Award · Derivative | 9,300 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001520262-26-000027 · form4.xml · derivative · entry 6 Jackson Blair Curtis · CIK 0001842348 · EVP, Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,903 Underlying: Ordinary Shares · 9,300 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share. F3 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/19/2026. F3 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/19/2026. Read SEC document |
| February 19, 2026 Filed Feb 20, 2026 21:23 UTC |
Jackson Blair CurtisEVP, Chief Operating Officer
|
Tax withholdingOrdinary Shares | 4,130 | $32.00 | $132,160.00 |
DisclosureSEC source: 0001520262-26-000027 · form4.xml · nonDerivative · entry 4 Jackson Blair Curtis · CIK 0001842348 · EVP, Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 231,823 Read SEC document |
| February 19, 2026 Filed Feb 20, 2026 21:23 UTC |
Jackson Blair CurtisEVP, Chief Operating Officer
|
Exercise / conversionOrdinary Shares | 9,300 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001520262-26-000027 · form4.xml · nonDerivative · entry 3 Jackson Blair Curtis · CIK 0001842348 · EVP, Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 235,953 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share. Read SEC document |
| February 19, 2026 Filed Feb 20, 2026 21:22 UTC |
Hopkinson Craig C.EVP R&D, Chief Medical Officer
|
Exercise / conversionRestricted Stock Unit Award · Derivative | 7,673 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001520262-26-000026 · form4.xml · derivative · entry 6 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,019 Underlying: Ordinary Shares · 7,673 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share. F3 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/19/2026. F3 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/19/2026. Read SEC document |
| February 19, 2026 Filed Feb 20, 2026 21:22 UTC |
Hopkinson Craig C.EVP R&D, Chief Medical Officer
|
Tax withholdingOrdinary Shares | 3,407 | $32.00 | $109,024.00 |
DisclosureSEC source: 0001520262-26-000026 · form4.xml · nonDerivative · entry 4 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 85,297 Read SEC document |
| February 19, 2026 Filed Feb 20, 2026 21:22 UTC |
Hopkinson Craig C.EVP R&D, Chief Medical Officer
|
Exercise / conversionOrdinary Shares | 7,673 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001520262-26-000026 · form4.xml · nonDerivative · entry 3 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 88,704 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share. Read SEC document |
| February 19, 2026 Filed Feb 20, 2026 21:20 UTC |
Gaffin David JosephEVP, CLO, Alkermes, Inc.
|
Exercise / conversionRestricted Stock Unit Award · Derivative | 7,673 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001520262-26-000025 · form4.xml · derivative · entry 6 Gaffin David Joseph · CIK 0001675905 · EVP, CLO, Alkermes, Inc. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,019 Underlying: Ordinary Shares · 7,673 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share. F3 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/19/2026. F3 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/19/2026. Read SEC document |
| February 19, 2026 Filed Feb 20, 2026 21:20 UTC |
Gaffin David JosephEVP, CLO, Alkermes, Inc.
|
Tax withholdingOrdinary Shares | 3,407 | $32.00 | $109,024.00 |
DisclosureSEC source: 0001520262-26-000025 · form4.xml · nonDerivative · entry 4 Gaffin David Joseph · CIK 0001675905 · EVP, CLO, Alkermes, Inc. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 231,602 Read SEC document |
| February 19, 2026 Filed Feb 20, 2026 21:20 UTC |
Gaffin David JosephEVP, CLO, Alkermes, Inc.
|
Exercise / conversionOrdinary Shares | 7,673 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001520262-26-000025 · form4.xml · nonDerivative · entry 3 Gaffin David Joseph · CIK 0001675905 · EVP, CLO, Alkermes, Inc. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 235,009 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share. Read SEC document |
| February 18, 2026 Filed Feb 20, 2026 21:24 UTC |
Nichols Christian ToddSVP, Chief Commercial Officer
|
Exercise / conversionRestricted Stock Unit Award · Derivative | 6,355 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001520262-26-000028 · form4.xml · derivative · entry 5 Nichols Christian Todd · CIK 0001813312 · SVP, Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 6,355 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share. F2 · derivative.exercise_date: This award is fully vested in accordance with its terms. F2 · derivative.expiration_date: This award is fully vested in accordance with its terms. Read SEC document |
| February 18, 2026 Filed Feb 20, 2026 21:24 UTC |
Nichols Christian ToddSVP, Chief Commercial Officer
|
Tax withholdingOrdinary Shares | 1,869 | $32.02 | $59,845.38 |
DisclosureSEC source: 0001520262-26-000028 · form4.xml · nonDerivative · entry 2 Nichols Christian Todd · CIK 0001813312 · SVP, Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 105,432 Read SEC document |
| February 18, 2026 Filed Feb 20, 2026 21:24 UTC |
Nichols Christian ToddSVP, Chief Commercial Officer
|
Exercise / conversionOrdinary Shares | 6,355 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001520262-26-000028 · form4.xml · nonDerivative · entry 1 Nichols Christian Todd · CIK 0001813312 · SVP, Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 107,301 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share. Read SEC document |
| February 18, 2026 Filed Feb 20, 2026 21:25 UTC |
Parisi Samuel JosephVP, Finance (Interim PAO)
|
Exercise / conversionRestricted Stock Unit Award · Derivative | 2,034 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001520262-26-000029 · form4.xml · derivative · entry 5 Parisi Samuel Joseph · CIK 0002010945 · VP, Finance (Interim PAO) 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 2,034 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share. F2 · derivative.exercise_date: This award is fully vested in accordance with its terms. F2 · derivative.expiration_date: This award is fully vested in accordance with its terms. Read SEC document |
| February 18, 2026 Filed Feb 20, 2026 21:25 UTC |
Parisi Samuel JosephVP, Finance (Interim PAO)
|
Tax withholdingOrdinary Shares | 706 | $32.02 | $22,606.12 |
DisclosureSEC source: 0001520262-26-000029 · form4.xml · nonDerivative · entry 2 Parisi Samuel Joseph · CIK 0002010945 · VP, Finance (Interim PAO) 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,045 Read SEC document |
| February 18, 2026 Filed Feb 20, 2026 21:25 UTC |
Parisi Samuel JosephVP, Finance (Interim PAO)
|
Exercise / conversionOrdinary Shares | 2,034 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001520262-26-000029 · form4.xml · nonDerivative · entry 1 Parisi Samuel Joseph · CIK 0002010945 · VP, Finance (Interim PAO) 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,751 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share. Read SEC document |
| February 18, 2026 Filed Feb 20, 2026 21:23 UTC |
Jackson Blair CurtisEVP, Chief Operating Officer
|
Exercise / conversionRestricted Stock Unit Award · Derivative | 8,897 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001520262-26-000027 · form4.xml · derivative · entry 5 Jackson Blair Curtis · CIK 0001842348 · EVP, Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 8,897 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share. F2 · derivative.exercise_date: This award is fully vested in accordance with its terms. F2 · derivative.expiration_date: This award is fully vested in accordance with its terms. Read SEC document |
| February 18, 2026 Filed Feb 20, 2026 21:23 UTC |
Jackson Blair CurtisEVP, Chief Operating Officer
|
Tax withholdingOrdinary Shares | 3,796 | $32.02 | $121,547.92 |
DisclosureSEC source: 0001520262-26-000027 · form4.xml · nonDerivative · entry 2 Jackson Blair Curtis · CIK 0001842348 · EVP, Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 226,653 Read SEC document |
| February 18, 2026 Filed Feb 20, 2026 21:23 UTC |
Jackson Blair CurtisEVP, Chief Operating Officer
|
Exercise / conversionOrdinary Shares | 8,897 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001520262-26-000027 · form4.xml · nonDerivative · entry 1 Jackson Blair Curtis · CIK 0001842348 · EVP, Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 230,449 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share. Read SEC document |
| February 18, 2026 Filed Feb 20, 2026 21:22 UTC |
Hopkinson Craig C.EVP R&D, Chief Medical Officer
|
Exercise / conversionRestricted Stock Unit Award · Derivative | 8,897 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001520262-26-000026 · form4.xml · derivative · entry 5 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 8,897 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share. F2 · derivative.exercise_date: This award is fully vested in accordance with its terms. F2 · derivative.expiration_date: This award is fully vested in accordance with its terms. Read SEC document |
| February 18, 2026 Filed Feb 20, 2026 21:22 UTC |
Hopkinson Craig C.EVP R&D, Chief Medical Officer
|
Tax withholdingOrdinary Shares | 3,504 | $32.02 | $112,198.08 |
DisclosureSEC source: 0001520262-26-000026 · form4.xml · nonDerivative · entry 2 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 81,031 Read SEC document |
| February 18, 2026 Filed Feb 20, 2026 21:22 UTC |
Hopkinson Craig C.EVP R&D, Chief Medical Officer
|
Exercise / conversionOrdinary Shares | 8,897 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001520262-26-000026 · form4.xml · nonDerivative · entry 1 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 84,535 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share. Read SEC document |
| February 18, 2026 Filed Feb 20, 2026 21:20 UTC |
Gaffin David JosephEVP, CLO, Alkermes, Inc.
|
Exercise / conversionRestricted Stock Unit Award · Derivative | 6,355 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001520262-26-000025 · form4.xml · derivative · entry 5 Gaffin David Joseph · CIK 0001675905 · EVP, CLO, Alkermes, Inc. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 6,355 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share. F2 · derivative.exercise_date: This award is fully vested in accordance with its terms. F2 · derivative.expiration_date: This award is fully vested in accordance with its terms. Read SEC document |
| February 18, 2026 Filed Feb 20, 2026 21:20 UTC |
Gaffin David JosephEVP, CLO, Alkermes, Inc.
|
Tax withholdingOrdinary Shares | 2,126 | $32.02 | $68,074.52 |
DisclosureSEC source: 0001520262-26-000025 · form4.xml · nonDerivative · entry 2 Gaffin David Joseph · CIK 0001675905 · EVP, CLO, Alkermes, Inc. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 227,336 Read SEC document |
| February 18, 2026 Filed Feb 20, 2026 21:20 UTC |
Gaffin David JosephEVP, CLO, Alkermes, Inc.
|
Exercise / conversionOrdinary Shares | 6,355 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001520262-26-000025 · form4.xml · nonDerivative · entry 1 Gaffin David Joseph · CIK 0001675905 · EVP, CLO, Alkermes, Inc. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 229,462 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share. Read SEC document |
| February 05, 2026 Filed Feb 7, 2026 00:14 UTC |
POPS RICHARD FDirector · Director and CEO, Alkermes plc
|
Tax withholdingOrdinary Shares | 62,230 | $33.55 | $2,087,816.50 |
DisclosureSEC source: 0001520262-26-000019 · form4.xml · nonDerivative · entry 2 POPS RICHARD F · CIK 0001126490 · Director · Director and CEO, Alkermes plc 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,377,740 Read SEC document |
| February 05, 2026 Filed Feb 7, 2026 00:14 UTC |
POPS RICHARD FDirector · Director and CEO, Alkermes plc
|
GrantOrdinary Shares | 149,580 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001520262-26-000019 · form4.xml · nonDerivative · entry 1 POPS RICHARD F · CIK 0001126490 · Director · Director and CEO, Alkermes plc 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,439,970 F1 · price: These ordinary shares were acquired by the reporting person as a result of the vesting of performance-vesting restricted stock unit awards granted to the reporting person on February 23, 2023 with a three-year performance period that ended on December 31, 2025 (the "2023 PRSUs"). The vesting of this portion of the 2023 PRSUs was triggered by the determination of achievement of certain pre-specified performance goals and application of a relative total shareholder return modifier and represents the final vesting event under the 2023 PRSUs. Read SEC document |
| February 05, 2026 Filed Feb 7, 2026 00:13 UTC |
Nichols Christian ToddSVP, Chief Commercial Officer
|
Tax withholdingOrdinary Shares | 6,389 | $33.55 | $214,350.95 |
DisclosureSEC source: 0001520262-26-000018 · form4.xml · nonDerivative · entry 2 Nichols Christian Todd · CIK 0001813312 · SVP, Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,946 Read SEC document |
| February 05, 2026 Filed Feb 7, 2026 00:13 UTC |
Nichols Christian ToddSVP, Chief Commercial Officer
|
GrantOrdinary Shares | 21,127 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001520262-26-000018 · form4.xml · nonDerivative · entry 1 Nichols Christian Todd · CIK 0001813312 · SVP, Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 107,335 F1 · price: These ordinary shares were acquired by the reporting person as a result of the vesting of performance-vesting restricted stock unit awards granted to the reporting person on February 23, 2023 with a three-year performance period that ended on December 31, 2025 (the "2023 PRSUs"). The vesting of this portion of the 2023 PRSUs was triggered by the determination of achievement of certain pre-specified performance goals and application of a relative total shareholder return modifier and represents the final vesting event under the 2023 PRSUs. Read SEC document |
| February 05, 2026 Filed Feb 7, 2026 00:12 UTC |
Jackson Blair CurtisEVP, Chief Operating Officer
|
Tax withholdingOrdinary Shares | 8,626 | $33.55 | $289,402.30 |
DisclosureSEC source: 0001520262-26-000017 · form4.xml · nonDerivative · entry 2 Jackson Blair Curtis · CIK 0001842348 · EVP, Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 221,552 Read SEC document |
| February 05, 2026 Filed Feb 7, 2026 00:12 UTC |
Jackson Blair CurtisEVP, Chief Operating Officer
|
GrantOrdinary Shares | 28,810 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001520262-26-000017 · form4.xml · nonDerivative · entry 1 Jackson Blair Curtis · CIK 0001842348 · EVP, Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 230,178 F1 · price: These ordinary shares were acquired by the reporting person as a result of the vesting of performance-vesting restricted stock unit awards granted to the reporting person on February 23, 2023 with a three-year performance period that ended on December 31, 2025 (the "2023 PRSUs"). The vesting of this portion of the 2023 PRSUs was triggered by the determination of achievement of certain pre-specified performance goals and application of a relative total shareholder return modifier and represents the final vesting event under the 2023 PRSUs. Read SEC document |
| February 05, 2026 Filed Feb 7, 2026 00:11 UTC |
Hopkinson Craig C.EVP R&D, Chief Medical Officer
|
Tax withholdingOrdinary Shares | 7,454 | $33.55 | $250,081.70 |
DisclosureSEC source: 0001520262-26-000016 · form4.xml · nonDerivative · entry 2 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,638 Read SEC document |
| February 05, 2026 Filed Feb 7, 2026 00:11 UTC |
Hopkinson Craig C.EVP R&D, Chief Medical Officer
|
GrantOrdinary Shares | 25,352 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001520262-26-000016 · form4.xml · nonDerivative · entry 1 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 83,092 F1 · price: These ordinary shares were acquired by the reporting person as a result of the vesting of performance-vesting restricted stock unit awards granted to the reporting person on February 23, 2023 with a three-year performance period that ended on December 31, 2025 (the "2023 PRSUs"). The vesting of this portion of the 2023 PRSUs was triggered by the determination of achievement of certain pre-specified performance goals and application of a relative total shareholder return modifier and represents the final vesting event under the 2023 PRSUs. Read SEC document |
| February 05, 2026 Filed Feb 7, 2026 00:11 UTC |
Gaffin David JosephEVP, CLO, Alkermes, Inc.
|
Tax withholdingOrdinary Shares | 7,619 | $33.55 | $255,617.45 |
DisclosureSEC source: 0001520262-26-000015 · form4.xml · nonDerivative · entry 2 Gaffin David Joseph · CIK 0001675905 · EVP, CLO, Alkermes, Inc. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 223,107 Read SEC document |
| February 05, 2026 Filed Feb 7, 2026 00:11 UTC |
Gaffin David JosephEVP, CLO, Alkermes, Inc.
|
GrantOrdinary Shares | 25,352 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001520262-26-000015 · form4.xml · nonDerivative · entry 1 Gaffin David Joseph · CIK 0001675905 · EVP, CLO, Alkermes, Inc. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 230,726 F1 · price: These ordinary shares were acquired by the reporting person as a result of the vesting of performance-vesting restricted stock unit awards granted to the reporting person on February 23, 2023 with a three-year performance period that ended on December 31, 2025 (the "2023 PRSUs"). The vesting of this portion of the 2023 PRSUs was triggered by the determination of achievement of certain pre-specified performance goals and application of a relative total shareholder return modifier and represents the final vesting event under the 2023 PRSUs. Read SEC document |
| February 02, 2026 Filed Feb 3, 2026 01:52 UTC |
Hopkinson Craig C.EVP R&D, Chief Medical Officer
|
Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $19.34 | $0.00 |
DisclosureSEC source: 0001520262-26-000009 · form4.xml · derivative · entry 4 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 26,356 Underlying: Ordinary Shares · 5,000 shares Expires 2031-02-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This option exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 3/14/2025. F4 · derivative.exercise_date: These options are fully vested in accordance with their terms. Read SEC document |
| February 02, 2026 Filed Feb 3, 2026 01:52 UTC |
Hopkinson Craig C.EVP R&D, Chief Medical Officer
|
SaleOrdinary Shares | 4,000 | $33.54 | $134,160.00 |
DisclosureSEC source: 0001520262-26-000009 · form4.xml · nonDerivative · entry 3 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 57,740 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 3/14/2025. Read SEC document |
| February 02, 2026 Filed Feb 3, 2026 01:52 UTC |
Hopkinson Craig C.EVP R&D, Chief Medical Officer
|
SaleOrdinary Shares | 5,000 | $34.24 | $171,224.50 |
DisclosureSEC source: 0001520262-26-000009 · form4.xml · nonDerivative · entry 2 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 61,740 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 3/14/2025. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $33.67 to $34.64. Full information regarding the number of shares sold at each separate price can be provided to the issuer, any security holder of the issuer or the SEC staff upon request. Read SEC document |
| February 02, 2026 Filed Feb 3, 2026 01:52 UTC |
Hopkinson Craig C.EVP R&D, Chief Medical Officer
|
Exercise / conversionOrdinary Shares | 5,000 | $19.34 | $96,700.00 |
DisclosureSEC source: 0001520262-26-000009 · form4.xml · nonDerivative · entry 1 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 66,740 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This option exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 3/14/2025. Read SEC document |
| February 02, 2026 Filed Feb 3, 2026 01:48 UTC |
Cooke ShaneDirector
|
Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 61,200 | $0.00 Strike: $31.64 | $0.00 |
DisclosureSEC source: 0001520262-26-000008 · form4.xml · derivative · entry 4 Cooke Shane · CIK 0001524823 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 61,200 shares Expires 2026-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise and sale of expiring options was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 2/27/25. F4 · derivative.exercise_date: These options are fully vested in accordance with their terms. Read SEC document |
| February 02, 2026 Filed Feb 3, 2026 01:48 UTC |
Cooke ShaneDirector
|
SaleOrdinary Shares | 32,113 | $34.78 | $1,116,877.29 |
DisclosureSEC source: 0001520262-26-000008 · form4.xml · nonDerivative · entry 3 Cooke Shane · CIK 0001524823 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 103,744 F1 · kind: This exercise and sale of expiring options was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 2/27/25. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $34.70 to $34.91. Full information regarding the number of shares sold at each separate price can be provided to the issuer, any security holder of the issuer or the SEC staff upon request. Read SEC document |
| February 02, 2026 Filed Feb 3, 2026 01:48 UTC |
Cooke ShaneDirector
|
SaleOrdinary Shares | 29,087 | $34.34 | $998,795.22 |
DisclosureSEC source: 0001520262-26-000008 · form4.xml · nonDerivative · entry 2 Cooke Shane · CIK 0001524823 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 135,857 F1 · kind: This exercise and sale of expiring options was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 2/27/25. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $33.6923 to $34.69. Full information regarding the number of shares sold at each separate price can be provided to the issuer, any security holder of the issuer or the SEC staff upon request. Read SEC document |
| February 02, 2026 Filed Feb 3, 2026 01:48 UTC |
Cooke ShaneDirector
|
Exercise / conversionOrdinary Shares | 61,200 | $31.64 | $1,936,368.00 |
DisclosureSEC source: 0001520262-26-000008 · form4.xml · nonDerivative · entry 1 Cooke Shane · CIK 0001524823 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 164,944 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise and sale of expiring options was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 2/27/25. Read SEC document |
| January 08, 2026 Filed Jan 8, 2026 22:23 UTC |
Hopkinson Craig C.EVP R&D, Chief Medical Officer
|
Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $19.34 | $0.00 |
DisclosureSEC source: 0001520262-26-000004 · form4.xml · derivative · entry 3 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 31,356 Underlying: Ordinary Shares · 5,000 shares Expires 2031-02-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This option exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 3/14/2025. F4 · derivative.exercise_date: These options are fully vested in accordance with their terms. Read SEC document |
| January 08, 2026 Filed Jan 8, 2026 22:23 UTC |
Hopkinson Craig C.EVP R&D, Chief Medical Officer
|
SaleOrdinary Shares | 5,000 | $30.00 | $150,005.00 |
DisclosureSEC source: 0001520262-26-000004 · form4.xml · nonDerivative · entry 2 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 61,740 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 3/14/2025. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $30.00 to $30.01. Full information regarding the number of shares sold at each separate price can be provided to the issuer, any security holder of the issuer or the SEC staff upon request. Read SEC document |
| January 08, 2026 Filed Jan 8, 2026 22:23 UTC |
Hopkinson Craig C.EVP R&D, Chief Medical Officer
|
Exercise / conversionOrdinary Shares | 5,000 | $19.34 | $96,700.00 |
DisclosureSEC source: 0001520262-26-000004 · form4.xml · nonDerivative · entry 1 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 66,740 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This option exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 3/14/2025. Read SEC document |
| January 02, 2026 Filed Jan 2, 2026 21:39 UTC |
Hopkinson Craig C.EVP R&D, Chief Medical Officer
|
SaleOrdinary Shares | 4,000 | $28.00 | $112,000.00 |
DisclosureSEC source: 0001520262-26-000002 · form4.xml · nonDerivative · entry 1 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 61,740 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 3/14/2025. Read SEC document |
| December 03, 2025 Filed Dec 5, 2025 21:21 UTC |
Hopkinson Craig C.EVP R&D, Chief Medical Officer
|
Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 3,748 | $0.00 Strike: $19.34 | $0.00 |
DisclosureSEC source: 0001520262-25-000014 · form4.xml · derivative · entry 3 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 36,356 Underlying: Ordinary Shares · 3,748 shares Expires 2031-02-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This option exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 3/14/2025. F4 · derivative.exercise_date: These options are fully vested in accordance with their terms. Read SEC document |
| December 03, 2025 Filed Dec 5, 2025 21:21 UTC |
Hopkinson Craig C.EVP R&D, Chief Medical Officer
|
SaleOrdinary Shares | 3,748 | $30.00 | $112,447.12 |
DisclosureSEC source: 0001520262-25-000014 · form4.xml · nonDerivative · entry 2 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 65,740 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 3/14/2025. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $30.00 to $30.03. Full information regarding the number of shares sold at each separate price can be provided to the issuer, any security holder of the issuer or the SEC staff upon request. Read SEC document |
| December 03, 2025 Filed Dec 5, 2025 21:21 UTC |
Hopkinson Craig C.EVP R&D, Chief Medical Officer
|
Exercise / conversionOrdinary Shares | 3,748 | $19.34 | $72,486.32 |
DisclosureSEC source: 0001520262-25-000014 · form4.xml · nonDerivative · entry 1 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 69,488 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This option exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 3/14/2025. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.